A Study of SYH2092 Injection in Healthy Participants

Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Study ID
NCT07776041
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Overweight or Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • SYH2092 Injection — DRUG
    Conduct in accordance with the study protocol.
  • Placebo — DRUG
    Conduct in accordance with the study protocol.

Study Details

To evaluate the safety and tolerability of SYH2092 Injection in healthy participants

Key Dates

First listed
Aug 20, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Feb 9, 2027
Completion
Apr 20, 2027

Study Design

Enrollment
46 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SYH2092 Injection
  • Placebo Comparator: Placebo

Primary Outcome Measure

Number of participants with treatment-related adverse events as accessed by CTCAE v6.0 [ Time Frame: Screening period up to day 71 ]

Central Contacts

Related Studies